Biliary and renal excretions of cefpiramide in Eisai hyperbilirubinemic rats. 1995

I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
Department of Hospital Pharmacy, Nagoya University School of Medicine, Japan.

Eisai hyperbilirubinemic mutant rats (EHBRs) with conjugated hyperbilirubinemia were recently derived from Sprague-Dawley rats (SDRs). The pharmacokinetic characteristics of the beta-lactam antibiotic cefpiramide (CPM), which is mainly excreted into bile, were investigated in 10- and 20-week-old EHBRs and were compared with those in 20-week-old healthy SDRs. The pharmacokinetic parameters of CPM after an intravenous administration of 20 mg/kg of body weight were estimated for each rat by noncompartmental methods. When compared with age-matched healthy SDRs, significant decreases (by approximately 30%) in the systemic clearance of CPM were observed in 20-week-old EHBRs. The biliary clearance of CPM in 20-week-old EHBRs markedly decreased to less than 10% of that in age-matched healthy SDRs, while total urinary recovery of unchanged CPM increased to threefold and renal clearance doubled. However, no significant differences in any of the pharmacokinetic parameters of CPM were observed between the two groups of EHBRs. There were no significant differences among the three groups in the steady-state volume of distribution of CPM. The present study indicates that hyperbilirubinemia induces an increase in the urinary excretion ability of CPM in return for a reduction in the biliary excretion.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011922 Rats, Mutant Strains Rats bearing mutant genes which are phenotypically expressed in the animals. Mutant Strains Rat,Mutant Strains Rats,Rat, Mutant Strains,Strains Rat, Mutant,Strains Rats, Mutant
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D006932 Hyperbilirubinemia A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdown product of HEME, is normally excreted in the BILE or further catabolized before excretion in the urine. Bilirubinemia,Bilirubinemias,Hyperbilirubinemias
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
August 1995, Digestive diseases and sciences,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
July 1996, Hepatology (Baltimore, Md.),
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
March 1997, Digestive diseases and sciences,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
January 1996, Biological trace element research,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
September 1995, The Journal of pharmacology and experimental therapeutics,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
January 1992, The Journal of biological chemistry,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
January 1994, Drug metabolism and disposition: the biological fate of chemicals,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
January 2003, Pharmaceutical research,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
June 1993, The Journal of pharmacology and experimental therapeutics,
I Muraoka, and T Hasegawa, and M Nadai, and L Wang, and S Haghgoo, and O Tagaya, and T Nabeshima
February 2006, Biochemical and biophysical research communications,
Copied contents to your clipboard!